SKI Market

A+| A| A-| Skip to Main Content

Indian Indices

Sensex

73,204.16 -505.53
( -0.69%)

Global Indices

Nasdaq

52,880.09 363.21
(0.69%)

Dow Jones

7,780.08 46.51
(0.60%)

Hang Seng

64,728.80 653.38
(1.02%)

Nikkei 225

10,751.68 18.68
(0.17%)

Forex

USD-INR

94.82 -0.08
(-0.09%)

EUR-INR

106.45 0.01
(0.01%)

GBP-INR

126.63 0.25
(0.20%)

JPY-INR

0.60 0.00
(-0.04%)

YOU ARE HERE :
HOME
Markets
Equity
Company News

EQUITY - MARKET SCREENER

Cipla Ltd

Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln

BSE Code

ISIN Demat

Book Value()

500087

INE059A01026

423.34903

NSE Symbol

P/E(TTM)

Mar.Cap( Cr.)

CIPLA

32.37

106138.04

EPS(TTM)

Face Value()

Div & Yield %

40.59

0.99

Date	Headline
05-Oct-2026	Cipla Ltd under sustained pressure
29-Sep-2026	Cipla to announce Quarterly Result
24-Sep-2026	Cipla allots 12,168 equity shares under ESOS
18-Sep-2026	Cipla receives ESG rating of 68
04-Sep-2026	Invagen Pharmaceuticals enters licensing agreement with Qilu
04-Sep-2026	Cipla inks exclusive partnership with Qilu Pharma for commercializing Pembrolizumab in US
01-Sep-2026	Cipla inks exclusive licensing agreement with SBP Group for ADC Rolditamig Deuderuxtecan
31-Aug-2026	Cipla and SBP Group sign exclusive license agreement for Rolditamig Deuderuxtecan
04-Aug-2026	InvaGen receives EIR report for its facility in Hauppauge, New York
23-Jul-2026	Cipla consolidated net profit declines 39.19% in the June 2026 quarter

<< < 1 2 3 ... > >>

73,204.16 -505.53 ( -0.69%)

52,880.09 363.21 (0.69%)

7,780.08 46.51 (0.60%)

64,728.80 653.38 (1.02%)

10,751.68 18.68 (0.17%)

94.82 -0.08 (-0.09%)

106.45 0.01 (0.01%)

126.63 0.25 (0.20%)

0.60 0.00 (-0.04%)